FLSM
ORKA

Frazier Life Sciences Management’s Oruka Therapeutics ORKA Stock Holding History

Frazier Life Sciences Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-583,327
Closed -$6.54M – 53
2025
Q2 		$6.54M Hold
583,327
– – 0.26% 43
2025
Q1 		$5.98M Hold
583,327
– – 0.27% 38
2024
Q4 		$11.3M Buy
583,327
+106,000
+22% +$2.59M 0.47% 34
2024
Q3 		$11.7M Buy
+477,327
New +$16.6M 0.47% 35

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Frazier Life Sciences Management's ORKA Position: Q3 2025 in Review

Frazier Life Sciences Management sold out of Oruka Therapeutics (ORKA) in Q3 2025, closing a stake of 583,327 shares — an estimated $6.54M sold.

Frazier Life Sciences Management first reported a position in ORKA in Q3 2024 and held it in 4 quarters. The position peaked at $11.7M in Q3 2024. 105 funds tracked by Wall St. Rank hold ORKA as of Q3 2025.

  • Frazier Life Sciences Management reported no remaining Oruka Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 583,327 Oruka Therapeutics shares in Q3 2025, an estimated $6.54M.
  • Frazier Life Sciences Management first reported a position in Oruka Therapeutics in Q3 2024 and held it in 4 quarters.
  • Frazier Life Sciences Management's Oruka Therapeutics position peaked at $11.7M in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2025.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.